

Anti-inflammatory Therapeutics Market in Asia-Pacific See Huge Growth \$40.5 Billion by 2032 With CAGR of 5.4% : AMR

The Asia-Pacific anti-inflammatory therapeutics market growth is driven by increase in R&D activities for novel medication development.

WILMINGTON, DELAWARE, UNITED STATES, July 10, 2024 /EINPresswire.com/ -- According to the report, the [Asia-Pacific anti-inflammatory therapeutics market](#) was estimated at in \$100.0 billion in 2022, and is anticipated to hit by 2032, \$140.5 billion registering a CAGR of 5.4% from 2023 to 2033.



Asia-Pacific anti-inflammatory therapeutics market 2023 - 2032

For more information, please contact Allied Market Research at info@alliedmarketresearch.com or visit our website at <https://www.alliedmarketresearch.com/request-sample/1175>

“

Increase in number of people suffering from inflammatory diseases, surge in use of anti-inflammatory therapeutics, and strong product pipeline drive the growth.”

Allied Market Research

“

Increase in the prevalence of inflammatory diseases such as arthritis, inflammatory bowel diseases and others and surge use of corticosteroids to treat various inflammatory diseases drive the growth of the Asia-Pacific anti-inflammatory therapeutics market. However, side effects associated with the corticosteroids and NSAIDs are hampering the Asia-Pacific anti-inflammatory therapeutics market growth. On the contrary, increase in research and development activities for the development of novel anti-

inflammatory therapeutics is expected to offer remunerative opportunity for expansion of the Asia-Pacific anti-inflammatory therapeutics market during the forecast period.

□□□□□ □□□□□□□□ & □□□□□□□□:

□□□□□□□□ □□□□□□- □□□□-□□□□
□□□□ □□□□- □□□□
□□□□□□ □□□□ □□ □□□□- \$□□.□ □□□□□□□□
□□□□□□ □□□□ □□ □□□□- \$□□.□ □□□□□□□□
□□□□- □.□□%
□□. □□ □□□□□ □□ □□□□□□□□- □□□

□□□□□□□□□□ □□□□□□□□□□

- In the economic recession, the anti-inflammatory therapeutics market is driven by increase in prevalence of inflammatory diseases.
- However, fluctuations in the demand for pharmaceuticals including anti-inflammatory therapeutics as companies adjust their spending priorities impact the anti-inflammatory therapeutics market growth.

□□□□ □□ □□□□□□□□ □□□□□□, □□□□□□□□ □□ □□□ □□□□□□□□ -
<https://www.alliedmarketresearch.com/connect-to-analyst/1175>

□□□ □□□□□□□□□□ □□□□□□□□ □□ □□□□□□□□ □□□ □□□□ □□□□□□□□ □□□□□□ □□□ □□□□□□□□ □□□□□□

Based on indication, the arthritis segment accounted for the largest share in 2022, and is the fastest growing segment during the forecast period, contributing to nearly two-fifths of the Asia-Pacific anti-inflammatory therapeutics market revenue, owing to, increase in prevalence of arthritis and surge in number of people taking treatment for arthritis.

□□□ □□□□□□□□□□ □□□□□□□□ □□ □□□□□□□□ □□□ □□□□□□□□□□ □□□□□□ □□□□□□□□□□ □□□ □□□□□□□□ □□□□□□

Based on drug class, the biologics segment held the highest market share in 2022, and is the fastest growing segment during the forecast period, accounting for more than two-fifths of the anti-inflammatory therapeutics market revenue, owing to increase in use of biologics for the treatment of arthritis and other inflammatory diseases.

□□□ □□□□ □□□□□□ □□□ □□□□□□ □□□□□□□□□□□ □□□□□□□□ □□ □□□□□□□□ □□□ □□□□□□□□□□ □□□□□□ □□□□□□□□□□ □□□□□□

Based on distribution channel, the drug stores and retail pharmacies segment held the highest market share in 2022, and is the fastest growing segment during the forecast period, accounting for nearly two-fifths of the Asia-Pacific anti-inflammatory therapeutics market revenue, owing to increase in sell of anti-inflammatory drugs through retail pharmacy stores and rise in number of

people suffering from various inflammatory diseases.

□□□ □□□□□□□□□□ □□□□□□□□□□ -

<https://www.alliedmarketresearch.com/purchase-enquiry/1175>

□□□□□□ □□□□□□ □□□□□□: -

Abbvie Inc.

Amgen Inc.

Pfizer Inc.

GalaxoSmithKline plc

F. Hoffmann-La Roche Ltd.

Johnson and Johnson

Novartis AG

Eli Lilly and Company

Bayer AG

AstraZeneca plc

The report provides a detailed analysis of these key players of the Asia-Pacific anti-inflammatory therapeutics market. These players have adopted strategies such as, product launch and product approval to increase their market share and maintain dominant shares in different countries. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.

□□□□□ □□□□□□ □□□□□□ □□□□□□□□□□:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology

includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa

Allied Market Research

+1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/726485423>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.